Patent: 5,728,677
✉ Email this page to a colleague
Summary for Patent: 5,728,677
| Title: | Methods of inhibiting T-cell dependent proliferation of peripheral blood lymphocytes using the CD2-binding domain of lymphocyte function associated antigen 3 |
| Abstract: | Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed. |
| Inventor(s): | Wallner; Barbara P. (Cambridge, MA), Miller; Glenn T. (Haverhill, MA), Rosa; Margaret D. (Winchester, MA) |
| Assignee: | Biogen, Inc. (Cambridge, MA) |
| Application Number: | 08/459,512 |
| Patent Claims: | see list of patent claims |
Details for Patent 5,728,677
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Astellas Pharma Us, Inc. | AMEVIVE | alefacept | For Injection | 125036 | 01/30/2003 | ⤷ Try a Trial | 2015-03-17 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 5,728,677
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | 193724 | ⤷ Try a Trial |
| Australia | 1754092 | ⤷ Try a Trial |
| Australia | 660981 | ⤷ Try a Trial |
| Brazil | 1100443 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
